Efficacy and Safety of Hydroxychloroquine in Patients with IgA Nephropathy: A Meta-Analysis

被引:1
作者
Zhang, Zhe [1 ]
Liu, Xiaoyi [1 ]
Ye, Peiyi [1 ]
Xie, Chao [1 ]
Kong, Yaozhong [1 ]
机构
[1] First Peoples Hosp Foshan, Nephrol Dept, Foshan 528000, Guangdong, Peoples R China
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2024年 / 77卷 / 01期
关键词
efficacy; hydroxychloroquine; IgA nephropathy; meta-analysis; safety; RISK-FACTORS; RECOMMENDATIONS; PROTEINURIA; TERM;
D O I
10.56434/j.arch.esp.urol.20247701.2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: The purpose of this study was to determine efficacy and safety of hydroxychloroquine (HCQ) for patients with IgA nephropathy (IgAN). Methods: PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Wanfang database, Chinese National Knowledge Infrastructure and VIP database up to February 2023 were searched for associated studies comparing HCQ with any other nonHCQ for treating IgAN. The effects of proteinuria, a 50% decrease in proteinuria, estimated glomerular filtration rate (eGFR) and adverse events in patients with IgAN were examined in a meta-analysis. Data were extracted and pooled using RevMan 5.3. Results: Three randomized controlled trials (RCTs), two retrospective and two prospective studies (675 patients) that matched our inclusion criteria were identified. Compared with a control group, HCQ significantly reduced proteinuria (mean difference (MD): -0.26, 95% confidence interval (CI): -0.44 to -0.08, p < 0.01). Patients receiving HCQ plus renin-angiotensin system inhibitors (RASSi) had a better efficacy in proteinuria alleviation and a 50% decrease in proteinuria compared with control groups (MD: -0.38, 95% CI: -0.50 to -0.25, p < 0.001 and relative risk (RR) = 3.31, 95% CI: 1.73 to 6.36, p < 0.001). No appreciable variations were observed in eGFR between HCQ groups and control groups in treating patients with IgAN (MD: -2.00, 95% CI: -4.36 to 0.36, p = 0.10). Moreover, no serious adverse events were observed during HCQ treatment. Conclusions: Our results indicate HCQ is an efficient, secure treatment for IgAN.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 31 条
[1]   Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy [J].
Bagchi, Soumita ;
Bhowmik, Dipankar ;
Singh, Geetika ;
Agarwal, Sanjay Kumar .
KIDNEY INTERNATIONAL REPORTS, 2022, 7 (06) :1443-1444
[2]   KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis [J].
Beck, Laurence ;
Bomback, Andrew S. ;
Choi, Michael J. ;
Holzman, Larry B. ;
Langford, Carol ;
Mariani, Laura H. ;
Somers, Michael J. ;
Trachtman, Howard ;
Waldman, Meryl .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (03) :403-441
[3]   Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy? [J].
Ciferska, Hana ;
Honsova, Eva ;
Lodererova, Alena ;
Hruskova, Zdenka ;
Neprasova, Michaela ;
Vachek, Jan ;
Suchanek, Miloslav ;
Zima, Tomas ;
Coppo, Rosanna ;
Tesar, Vladimir ;
Novak, Jan ;
Maixnerova, Dita .
JOURNAL OF NEPHROLOGY, 2020, 33 (02) :307-316
[4]   2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [J].
Fanouriakis, Antonis ;
Kostopoulou, Myrto ;
Cheema, Kim ;
Anders, Hans-Joachim ;
Aringer, Martin ;
Bajema, Ingeborg ;
Boletis, John ;
Frangou, Eleni ;
Houssiau, Frederic A. ;
Hollis, Jane ;
Karras, Adexandre ;
Marchiori, Francesca ;
Marks, Stephen D. ;
Moroni, Gabriella ;
Mosca, Marta ;
Parodis, Ioannis ;
Praga, Manuel ;
Schneider, Matthias ;
Smolen, Josef S. ;
Tesar, Vladimir ;
Trachana, Maria ;
van Vollenhoven, Ronald F. ;
Voskuyl, Alexandre E. ;
Teng, Y. K. Onno ;
van Leew, Bernadette ;
Bertsias, George ;
Jayne, David ;
Boumpas, Dimitrios T. .
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) :713-723
[5]   Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy [J].
Gao, Ruitong ;
Wu, Wei ;
Wen, Yubing ;
Li, Xuemei .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (07) :1233-1241
[6]   Y Comparative efficacy of different renin angiotensin system blockade therapies in patients with IgA nephropathy: a Bayesian network meta-analysis of 17 RCTs [J].
Huo, Zhihao ;
Ye, Huizhen ;
Ye, Peiyi ;
Xiao, Guanqing ;
Zhang, Zhe ;
Kong, Yaozhong .
PEERJ, 2021, 9
[7]   Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis [J].
Inker, Lesley A. ;
Mondal, Hasi ;
Greene, Tom ;
Masaschi, Taylor ;
Locatelli, Francesco ;
Schena, Francesco P. ;
Katafuchi, Ritsuko ;
Appel, Gerald B. ;
Maes, Bart D. ;
Li, Philip K. ;
Praga, Manuel ;
Del Vecchio, Lucia ;
Andrulli, Simeone ;
Manno, Carlo ;
Gutierrez, Eduardo ;
Mercer, Alex ;
Carroll, Kevin J. ;
Schmid, Christopher H. ;
Levey, Andrew S. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (03) :392-401
[8]   Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].
Jadad, AR ;
Moore, RA ;
Carroll, D ;
Jenkinson, C ;
Reynolds, DJM ;
Gavaghan, DJ ;
McQuay, HJ .
CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12
[9]   Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy [J].
Lai, Kar Neng ;
Leung, Joseph C. K. ;
Chan, Loretta Y. Y. ;
Saleem, Moin A. ;
Mathieson, Peter W. ;
Tam, Ka Ying ;
Xiao, Jing ;
Lai, Fernand M. ;
Tang, Sydney C. W. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (01) :62-72
[10]   Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population [J].
Le, WeiBo ;
Liang, ShaoShan ;
Hu, YangLin ;
Deng, KangPing ;
Bao, Hao ;
Zeng, CaiHong ;
Liu, ZhiHong .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) :1479-1485